ILMN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.10B

-0.15%

1.223

+42.23%

1.06B

+1.53%

1.112

+14.61%

1.08B

+2.09%

1.241

+4.28%

Estimates Revision

The market is revising Upward the revenue expectations for Illumina, Inc. (ILMN) for FY2025, with the revenue forecasts being adjusted by 0.59% over the past three months. During the same period, the stock price has changed by 49.14%.

Revenue Estimates for FY2025

Revise Upward

+0.59%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+4.64%

In Past 3 Month

Stock Price

Go Up

+49.14%

In Past 3 Month

12 Analyst Rating

Wall Street analysts forecast ILMN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ILMN is 117.25 USD with a low forecast of 80.00 USD and a high forecast of 195.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

5 Hold

3 Sell

Hold

Current: 0.000

Low

80.00

Averages

117.25

High

195.00

Current: 0.000

Low

80.00

Averages

117.25

High

195.00

TD Cowen

Hold

maintain

$115 -> $140

2026-01-07

New

Reason

TD Cowen

Price Target

$115 -> $140

2026-01-07

New

maintain

Hold

Reason

TD Cowen raised the firm's price target on Illumina to $140 from $115 and keeps a Hold rating on the shares. The firm adjusted targets in the life science tools space as part of a Q4 outlook. While the bar is higher for the Q4 results following the recent share rallies, many companies "already soft guided" 2026, the analyst tells investors in a research note. TD believes this sets room for upside in 2026.

Guggenheim

Buy

maintain

$114 -> $144

2026-01-05

New

Reason

Guggenheim

Price Target

$114 -> $144

2026-01-05

New

maintain

Buy

Reason

Guggenheim raised the firm's price target on Illumina to $144 from $114 and keeps a Buy rating on the shares. The firm adjusted its models and forecasts for its covered Diagnostics and Life Sciences Tools companies to reflect recent updates from the companies after meetings with management teams.

Evercore ISI

Vijay Kumar

Outperform

maintain

$142 -> $155

2026-01-05

New

Reason

Evercore ISI

Vijay Kumar

Price Target

$142 -> $155

2026-01-05

New

maintain

Outperform

Reason

Evercore ISI analyst Vijay Kumar raised the firm's price target on Illumina to $155 from $142 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have "set the stage for a 2026 Tools play," the analyst tells investors. In MedTech, the firm's survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes "have bears watching," the analyst added.

Canaccord

Kyle Mikson

Hold

maintain

$112 -> $130

2025-12-22

Reason

Canaccord

Kyle Mikson

Price Target

$112 -> $130

2025-12-22

maintain

Hold

Reason

Canaccord analyst Kyle Mikson raised the firm's price target on Illumina to $130 from $112 and keeps a Hold rating on the shares. The firm previewed its life science tools and diagnostics covereage and believes momentum in the sector which began in the second half of this year, can be maintained in 2026. Among their covered companies, they see a key catalyst in 2026 for Illumina with its AXELIOS luanch with Roche Holdings.

JPMorgan

Casey Woodring

Neutral

maintain

$105 -> $130

2025-12-15

Reason

JPMorgan

Casey Woodring

Price Target

$105 -> $130

2025-12-15

maintain

Neutral

Reason

JPMorgan analyst Casey Woodring raised the firm's price target on Illumina to $130 from $105 and keeps a Neutral rating on the shares. The firm updated models in the life science tools and diagnostics group.

Barclays

Underweight

maintain

$100 -> $110

2025-12-15

Reason

Barclays

Price Target

$100 -> $110

2025-12-15

maintain

Underweight

Reason

Barclays raised the firm's price target on Illumina to $110 from $100 and keeps an Underweight rating on the shares. The firm adjusted ratings and price targets in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the "most under-owned space in healthcare" creates a "great setup" for outperformance of the tools group in 2026, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Illumina Inc (ILMN.O) is 27.36, compared to its 5-year average forward P/E of 80.15. For a more detailed relative valuation and DCF analysis to assess Illumina Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

80.15

Current PE

27.36

Overvalued PE

132.90

Undervalued PE

27.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

39.87

Current EV/EBITDA

17.73

Overvalued EV/EBITDA

61.24

Undervalued EV/EBITDA

18.50

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

7.30

Current PS

4.72

Overvalued PS

11.22

Undervalued PS

3.39

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ILMN News & Events

Events Timeline

No data

News

5.0

22:22 PMNewsfilter

Illumina Appoints Genomics Leader Eric Green as Chief Medical Officer

5.0

21:51 PMPRnewswire

Illumina Appoints Genomics Leader Eric D. Green as Chief Medical Officer

7.5

13:32 PMGlobenewswire

Illumina Partners with CGMH to Expand Cancer Genomic Profiling Access

People Also Watch

Frequently Asked Questions

What is Illumina Inc (ILMN) stock price today?

The current price of ILMN is 145.83 USD — it has decreased -2.87 % in the last trading day.

What is Illumina Inc (ILMN)'s business?

Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.

What is the price predicton of ILMN Stock?

What is Illumina Inc (ILMN)'s revenue for the last quarter?

Illumina Inc revenue for the last quarter amounts to 1.08B USD, increased 0.37 % YoY.

What is Illumina Inc (ILMN)'s earnings per share (EPS) for the last quarter?

Illumina Inc. EPS for the last quarter amounts to 0.97 USD, decreased -78.00 % YoY.

What changes have occurred in the market's expectations for Illumina Inc (ILMN)'s fundamentals?

How many employees does Illumina Inc (ILMN). have?

Illumina Inc (ILMN) has 8970 emplpoyees as of January 08 2026.

What is Illumina Inc (ILMN) market cap?

Today ILMN has the market capitalization of 22.28B USD.